In vitro cytotoxic activity required to inhibit human estrogen-sensitive breast adenocarcinoma MCF-7 cell line
CC(CCl)NC(=O)NC1=CC2=C(CC3=CC=CC=C32)C=C1,29000
CC(CCl)NC(=O)NC1=CC2=C(CC3=CC=CC=C32)C=C1,10000
C1=CC=C2C=C(C=CC2=C1)NC(=O)NCCCl,7300
CCC(CCl)NC(=O)NC1=CC=C(C=C1)I,80000
CCC(CCl)NC(=O)NC1=CC=C(C=C1)I,52000
CC(CCl)NC(=O)NC1=CC=C(C=C1)I,93000
CC(CCl)NC(=O)NC1=CC=C(C=C1)I,3200
C1=CC(=CC=C1NC(=O)NCCCl)I,23000
CC(CCl)NC(=O)NC1=CC2=CC=CC=C2C=C1,100000
CC(CCl)NC(=O)NC1=CC2=CC=CC=C2C=C1,6000
CC(CCl)NC(=O)NC1=CC=C(C=C1)C(C)(C)C,10000
CC(CCl)NC(=O)NC1=CC=C(C=C1)C(C)(C)C,84000
CCC(C)C1=CC=C(C=C1)NC(=O)NC(C)CCl,4800
CCC(CCl)NC(=O)NC1=CC=C(C=C1)C(C)(C)C,60000
CCC(CCl)NC(=O)NC1=CC=C(C=C1)C(C)C,72000
CCC(C)C1=CC=C(C=C1)NC(=O)NC(CC)CCl,38000
CC(C)(C)C1=CC=C(C=C1)NC(=O)NCCCl,11000
CC(C)C1=CC=C(C=C1)NC(=O)NC(C)CCl,100000
CC(C)C1=CC=C(C=C1)NC(=O)NCCCl,4700
CC(C)C1=CC=C(C=C1)NC(=O)NC(C)CCl,2900
CCC(CCl)NC(=O)NC1=CC=C(C=C1)C(C)C,55000
CCC(C)C1=CC=C(C=C1)NC(=O)NC(C)CCl,63000
CC(CCl)NC(=O)NC1=CC2=C(CCC2)C=C1,100000
CC(CCl)NC(=O)NC1=CC2=C(CCC2)C=C1,11000
CCC(CCl)NC(=O)NC1=CC=C(C=C1)C(C)(C)C,52000
CCC(C)C1=CC=C(C=C1)NC(=O)NCCCl,5200
CCC(C)C1=CC=C(C=C1)NC(=O)NC(CC)CCl,51000
